(Q35073345)

6 August 2017

1 reference

title

Novel antibacterial agents for the treatment of serious Gram-positive infections (English)

1 reference

6 August 2017

gram-positive bacteria

0 references

author name string

Darren Abbanat

series ordinal

1

1 reference

6 August 2017

Mark Macielag

series ordinal

2

1 reference

6 August 2017

Karen Bush

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

3

1 reference

6 August 2017

379-399

1 reference

Oxazolidinone antibiotics.

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Treatment options for vancomycin-resistant enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

21 January 2018

Glycopeptide derivatives

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Staphylococcus aureus mutants selected by BMS-284756.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro development of resistance to newer fluoroquinolones in Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

A critical review of the fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

The in vitro activity of BMS-284756, a new des-fluorinated quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Comparative antianaerobic activity of BMS 284756

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro and in vivo activities of sitafloxacin against Chlamydia spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Cardiotoxicity of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Mechanism of inhibition of protein synthesis by macrolide and lincosamide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Erythromycin binding is reduced in ribosomes with conformational alterations in the 23 S rRNA peptidyl transferase loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Ribosomal mutations in Streptococcus pneumoniae clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Macrolide resistance conferred by base substitutions in 23S rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

The in vitro activity of ABT773, a new ketolide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

In vitro activity of new ketolides against macrolide-susceptible and -resistant Staphylococcus aureus isolates with defined resistance gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Telithromycin: the first of the ketolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Telithromycin: an oral ketolide for respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Daptomycin: a novel agent for Gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Inhibition of membrane potential-dependent amino acid transport by daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.379

10.1517/13543784.12.3.379

21 January 2018

Identifiers

DOI

1 reference

release_dd67kvtngrcqfgahbynuwg2zum

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dd67kvtngrcqfgahbynuwg2zum

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference